Shanghai Ennovabio Pharmaceuticals Co., Ltd.

Merck Sharp + Dohme Corp.

Eccogene (shanghai) Co., Ltd.

Eccogene Inc.

Mingwei Zheng

Lei Jiang

Jingye Zhou

Yuan Xu

Jiuxiang Zhu

Ke Shang

Jianwen Deng

Jianyong Shou

Danyi Wu

Joseph P Vacca

Yi Zhang

Hao Wu

Craig Alan Coburn

Bin Hu

John A McCauley

Kun Liu

Fei Sun

Jianhua Zhang

Richard Soll

Zhiyong Feng

Jian Zhu

Steven W Ludmerer

Bin Zhong

Xinghai Wang

Bing Wang

Haixia Zhao

Xiaoping Xie

Xueli Xu

Shengyang Liu

Man Yan

Xudong Mao

Xiaoli Lu

Chengren Zhang

John A Mccauley

The application relates to a compound of Formula (I′) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I') or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.

Thyroid hormone receptor agonists and use thereof

Provided are a JAK kinase inhibitor, preparation and use thereof. In particular, provided is a compound of Formula I, wherein each group is as described in the specification. The compound has an excellent JAK inhibitory activity, and therefore can be used to prepare pharmaceutical compositions for the treatment of cancer and other diseases related to JAK activity.

Aromatic heterocyclic compound with kinase inhibitory activity

Provided are a compound for the prevention and treatment of diseases associated with PD-L1, a preparation method therefor and use thereof. Specifically, provided are the compound of formula I, the stereoisomer and the racemate thereof, or pharmaceutically acceptable salts thereof, and also provided is an application thereof in the preparation of a drug for the prevention and treatment of diseases associated with PD-L1.

Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof

The application relates to a compound of Formula (I') or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I&#x2032;) or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Inhibitors of hepatitis C virus replication

Growing community of inventors

Shanghai, China

Mingwei Zheng